Analytical Method Development and Validation of RP-HPLC Method for Estimation of Pazopanib Drug Sample and It’s Dosage Form

Suhas Shivaji Siddheshwar; Akshay Balu Kachare; Someshwar Dattatraya Mankar

doi:10.52756/ijerr.2023.v36.019

Suhas Shivaji Siddheshwar Department of Pharmaceutics, Pravara Rural College of Pharmacy, Pravaranagar, Rahata, Ahmednagar, 413736, Maharashtra, India https://orcid.org/0000-0002-7944-9470
Akshay Balu Kachare Department of Quality Assurance Techniques, Pravara Rural College of Pharmacy, Pravaranagar, Rahata, Ahmednagar, 413736, Maharashtra, India https://orcid.org/0009-0001-1456-0872
Someshwar Dattatraya Mankar Department of Pharmaceutics, Pravara Rural College of Pharmacy, Pravaranagar, Rahata, Ahmednagar, 413736, Maharashtra, India https://orcid.org/0000-0003-3991-9412

DOI: https://doi.org/10.52756/ijerr.2023.v36.019

Keywords: Pazopanib HCl, Pharmaceutical dosage forms, RP-HPLC, Validation

Abstract

The study focuses on developing and verifying a cost-effective Reverse Phase High-Performance Liquid Chromatography (RP-HPLC) technique for quantifying Pazopanib HCl in both bulk and tablet forms. The study aims to develop a cost-effective approach for routine quality control analysis by utilizing the simplicity and wide accessibility of HPLC. A Shimadzu C18 column (5 µm, 250 mm × 4.6 mm) was successfully used to separate Pazopanib HCl via chromatography. The mobile phase consisted of a mixture of Potassium dihydrogen phosphate in water (pH 2.9, corrected with Phosphoric Acid) and Acetonitrile in a ratio of 25:75 v/v. The isocratic elution mode was utilized with a flow rate of 1.0 mL/min, a column temperature of 25°C, and an injection volume of 20 µL. Pazopanib hydrochloride had a retention period of 2.8 minutes when measured at an isobestic wavelength of 215 nm. The described RP- HPLC technique showed exceptional specificity, accuracy, precision, linearity, and durability, rendering it a viable instrument for Pazopanib HCl tablets' regular quality control analysis. This method is both efficient in terms of analytical performance and economically profitable, making it very suitable for frequent pharmaceutical analysis.

References

Buralla, K. K., & Varadarajan P. (2020). Validated RP-HPLC Method Development of Pazopanib HCl in Bulk and its Pharmaceutical Dosage Form. Pharmaceutical Methods, 11(1), 21-24.

Chaitanya, G., & Pawar. A. K. M. (2015). Development and Validation of UV spectrophotometric method for the determination of Pazopanib hydrochloride in bulk and tablet formulation. Journal of Chemical and Pharmaceutical Research, 7(12), 219-225.

Escudero-Ortiz, V., Pérez-Ruixo, J. J., & Valenzuela, B. (2015). Development and validation of an HPLC-UV method for pazopanib quantification in human plasma and application to patients with cancer in routine clinical practice. Therapeutic Drug Monitoring, 37(2), 172–179. https://doi.org/10.1097/FTD.0000000000000121

Ghode, P. D., Dhaigude, P. U., Rathod, S. P., Sayare, A. S., Pachauri, A. D., Khandelwal, K., & Ghode, S. P. (2020). Stability Indicating HPTLC Method Development and Validation for the Estimation of Pazopanib HCL in Bulk and its Dosage Form. International Journal of Pharmaceutical Research, 12(3). https://doi.org/10.31838/ijpr/2020.12.03.518

Koylu, B., Tekin, F., Aktas B. Y., Kilickap. S., & Koksal. D. (2022). Pazopanib HCl -induced chylothorax in a patient with renal cell carcinoma. Anti-Cancer Drugs, 33(1), 555-557. https://doi.org/10.1097/CAD.0000000000001172

Ma, B., & Gou, X. L. (2016). Application of high-performance liquid chromatography in food and drug safety analysis. Journal of Food Safety and Quality, 7, 295-4298.

Minocha, M., Khurana, V., & Mitra, A. K. (2012). Determination of pazopanib (GW-786034) in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry (LC/MS-MS). Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 901, 85–92. https://doi.org/10.1016/j.jchromb.2012.06.004

Pressiat, C., Huynh, H. H., Plé, A., Sauvageon, H., Madelaine, I., Chougnet, C., Le Maignan, C., Mourah, S., & Goldwirt, L. (2018). Development and Validation of a Simultaneous Quantification Method of Ruxolitinib, Vismodegib, Olaparib, and Pazopanib in Human Plasma Using Liquid Chromatography Coupled With Tandem Mass Spectrometry. Therapeutic drug Monitoring, 40(3), 337–343.

https://doi.org/10.1097/FTD.0000000000000497

Patel, P. N., Kalariya, P. D., Sharma, M., Garg, P., Talluri, M. V., Gananadhamu, S., & Srinivas, R. (2015). Characterization of forced degradation products of pazopanib hydrochloride by UHPLC-Q-TOF/MS and in silico toxicity prediction. Journal of Mass Spectrometry: JMS, 50(7), 918–928. https://doi.org/10.1002/jms.3602

Ravi Sankar, P., Snehalatha S. K., Shaik, F. T., & Babu P. S. (2019). Applications of HPLC in Pharmaceutical Analysis. Int. J. Pharm.Sci. Rev. Res., 59(1), 117-124.

Ravi Sankar, P., Snehalatha S. K., Shaik, F. T., & Babu P. S. (2020). Development and validation of UV spectrophotometric method for the determination of Pazopanib Hydrochloride in pharmaceutical dosage form. Int. J. Pharm. Sci. Rev. Res., 61(2), 13-18.

Ravi Sankar, P., Saisneha Latha, K., Bhavani S. A., Taheera, S. K., & Madhuri, B. (2021). Development and validation of RP-HPLC method for the determination of Pazopanib Hydrochloride (A tyrosine kinase inhibitor) in pharmaceutical dosage form, Research Journal of Pharmacy and Technology, 14(3), 1549-1554.

https://doi.org/10.5958/0974-360X.2021.00273.0

Shabada, A., Fatima, N., Badar, H., & Sultana, S. S. (2017). Determination of Pazopanib hydrochloride in solid dosage form by RP-HPLC method: development and validation, Indo American Journal of Pharmaceutical Sciences, 4(11), 4094-4099. http://doi.org/10.5281/zenodo.1048471

Sparidans, R. W., Ahmed, T. T., Muilwijk, E. W., Welzen, M. E., Schellens, J. H., & Beijnen, J. H. (2012). Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the tyrosine kinase inhibitor pazopanib in human plasma. Journal of chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 905, 137–140. https://doi.org/10.1016/j.jchromb.2012.08.004

Sharada, M., & Babu, R. R. (2016). Determination and characterization of process impurities in pazopanib hydrochloride drug substance. International Journal of Pharmacy and Pharmaceutical Sciences, 8(4), 97–102.

Verheijen, R. V., Bins, S., Mathijssen, R. H., Lolkema, M. P., Van Doorn, L., Schellens, J. H., Beijnen, J. H., Langenberg, M. H., Huitema, A. D., & Steeghs, N. (2016). Individualized Pazopanib HCl dosing: a prospective feasibility study in cancer patients. Clinical Cancer Research, 22(23), 5738-46. http://dx.doi.org/10.1158/1078-0432.CCR-16-1255

Verheijen, R. B., Bins, S., Thijssen, B., Rosing, H., Nan, L., Schellens, J. H., Mathijssen, R. H., Lolkema, M. P., Beijnen, J. H., Steeghs, N., & Huitema, A. D. (2016). Development and clinical validation of an LC-MS/MS method for the quantification of pazopanib in DBS. Bioanalysis, 8(2), 123–134. https://doi.org/10.4155/bio.15.235

Verheijen, R. B., Thijssen, B., Rosing, H., Schellens, J. H. M., Nan, L., Venekamp, N., Beijnen, J. H., Steeghs, N., & Huitema, A. D. R. (2018). Fast and Straightforward Method for the Quantification of Pazopanib in Human Plasma Using LC-MS/MS. Therapeutic drug monitoring, 40(2), 230–236. https://doi.org/10.1097/FTD.0000000000000479